Top Markets
#1 OSK OSK +15.39%
#2 MarsCoin MarsCoin +12.21%
#3 Tornado Cash Tornado Cash +6.73%
#4 HOME HOME +6.37%
#5 UnifAI Network UnifAI Network +4.86%
#6 AI XOVIA AI XOVIA +4.25%
#7 Pyth Network Pyth Network +3.64%
#8 Backpack Backpack +3.30%
#9 Story Story +3.06%
#10 Rain Rain +2.82%
Coin of the day
OSK OSK
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Clasificación en acciones #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Precio por acción
$4.64
Última sincronización: 2022-09-12
Capitalización bursátil
$293.43M
Cambio (1 día)
0.87%
Cambio (1 año)
0.00%
País
US
Comercio Adagio Therapeutics, Inc. (ADGI)

Categoría

Healthcare
Ganancias de Adagio Therapeutics, Inc. (ADGI)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Adagio Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Adagio Therapeutics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH